SUBSCRIBE
SUBSCRIBE

Krystle Vermes

Drug Development
New Study Shows ‘Nanosponges’ May Help Neutralize the Coronavirus
A new study published on Wednesday in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.
June 18, 2020
 · 
3 min read
 · 
Krystle Vermes
BioMarin HQ/courtesy of BioMarin
Drug Development
BioMarin Shares Additional Promising Phase I/II Data on Hemophilia A Treatment
BioMarin Pharmaceutical released new data today from its previously reported four-year update of the open-label Phase I/II study of valoctocogene roxaparvovec.
June 17, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Could ‘Helper’ T Cells Pave the Way for COVID-19 Immunity?
Researchers found that certain individuals who have never been exposed to COVID-19 appear to have “helper” T cells that are capable of recognizing and responding to the virus.
June 17, 2020
 · 
2 min read
 · 
Krystle Vermes
Biotech Bay
4DMT to Use $75 Million Series C to Advance Three Key Pipeline Products
Before the end of this year, 4DMT intends to launch clinical trials for 4D-310, its product candidate for the treatment of Fabry disease, and 4D-125 and 4D-110, its two ophthalmology product candidates.
June 16, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Magenta Enters Collaboration Agreement with Beam to Further Explore MGTA-117
The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia.
June 15, 2020
 · 
3 min read
 · 
Krystle Vermes
Genetown
Checkmate Pharmaceuticals Raises $85M in Series C Funding to Expand Melanoma Research
Cambridge-based Checkmate Pharmaceuticals announced on Wednesday that it has completed an $85 million Series C round of financing, led by Longitude Capital and Novo Holdings.
June 11, 2020
 · 
2 min read
 · 
Krystle Vermes
Investor
FUJIFILM to Invest $928M in Denmark Biotech Development Site
With this capital investment, the site will be able to double its current drug substance manufacturing capacity and enhance its existing assembly operations. Production lines for bulk drug substance will be expanded, and development will begin on a new fill/finish production line.
June 10, 2020
 · 
3 min read
 · 
Krystle Vermes
Study Shows One Protein May Be Key to Preventing Pancreatic Cancer Metastasis
A study published in the Journal of Experimental Medicine on Monday revealed new research that showed pancreatic cancer metastasis may be suppressible by inhibiting a protein that regulates cell movement.
June 9, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Lundbeck to Revamp R&D Strategy and Eliminate Up to 160 Jobs
Lundbeck stated that it is optimizing its research and development organization to strengthen and advance its pipeline.
June 9, 2020
 · 
2 min read
 · 
Krystle Vermes
Drug Development
Scientists Eye Pepcid as a Potential Drug for Easing COVID-19 Symptoms
A small study that examined the use of famotidine in a group of 10 patients with COVID-19 suggests that the drug could potentially ease the symptoms of the condition.
June 8, 2020
 · 
3 min read
 · 
Krystle Vermes
Business
Daiichi Sankyo, Syneos Health Eye New Cancer Therapies with Collaboration Agreement
Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.
June 5, 2020
 · 
3 min read
 · 
Krystle Vermes
Deals
Aduro and Chinook to Merge, Launch New Clinical Trials for their Pipeline
When the transaction is completed, the combined company is expected to have about $200 million in cash, cash equivalents and marketable securities at closing.
June 2, 2020
 · 
3 min read
 · 
Krystle Vermes
StockStudio/Compressed
Drug Development
Pfizer Shares Dipped Following Release of Phase III Palbociclib Study Data
Pfizer shared results from the trial on Friday, and the data determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival in patients with breast cancer.
June 1, 2020
 · 
2 min read
 · 
Krystle Vermes
Business
Regeneron and Intellia Expand Their Hunt for Hemophilia A and B Treatments
Regeneron Pharmaceuticals and Intellia Therapeutics announced on Monday that they will be expanding an existing collaboration.
June 1, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM
The main Phase I monotherapy study had a favorable safety profile, showing that Ad+V was safely administered and tolerably in both craniotomy and stereotactic subjects.
May 29, 2020
 · 
3 min read
 · 
Krystle Vermes
Load More